Stocktoria
TANDEM DIABETES CARE INC TNDM
TANDEM DIABETES CARE INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $940.2M | $747.7M | $801.2M | $702.8M | $498.8M | $362.3M | $183.9M | $107.6M | $84.2M |
| Gross profit | $546.0M | $489.6M | $367.7M | $413.0M | $376.2M | $260.5M | $194.2M | $89.8M | $44.1M | $23.6M |
| R&D expense | — | — | — | — | $92.1M | $63.6M | $45.2M | $29.2M | $20.7M | $18.8M |
| SG&A expense | $445.0M | $389.8M | $352.5M | $335.7M | $261.5M | $204.9M | $165.7M | $105.2M | $86.4M | $82.8M |
| Operating income | -$187.3M | -$99.1M | -$233.2M | -$92.8M | $22.7M | -$8.0M | -$16.7M | -$44.6M | -$62.9M | -$78.1M |
| Income tax | $4.4M | $4.2M | $2.4M | $1.7M | $335,000 | -$1.9M | $149,000 | $51,000 | $8,000 | -$15,000 |
| Net income | -$204.7M | -$96.0M | -$222.6M | -$94.6M | $15.6M | -$34.4M | -$24.8M | -$122.6M | -$73.0M | -$83.4M |
| EPS (diluted) | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 | $-0.56 | $-0.42 | — | — | — |
| Operating cash flow | -$9.7M | $24.2M | -$31.8M | $50.5M | $111.4M | $24.7M | $41.9M | -$8.3M | -$66.1M | -$61.2M |
| Free cash flow | -$29.7M | $5.0M | -$58.6M | $16.4M | $97.2M | -$2.7M | $22.4M | -$11.3M | -$71.9M | -$70.1M |
| Cash & equivalents | $90.6M | $69.2M | $58.9M | $172.5M | $71.2M | $94.6M | $51.2M | $41.8M | $13.7M | $44.7M |
| Inventory | $128.8M | $149.6M | $157.9M | $111.1M | $68.6M | $63.7M | $49.1M | $19.9M | $27.0M | $21.2M |
| Total assets | $881.1M | $967.7M | $952.7M | $1.1B | $905.1M | $716.4M | $326.1M | $206.3M | $95.3M | $112.4M |
| Total liabilities | $725.9M | $704.6M | $639.0M | $612.8M | $472.0M | $350.1M | $131.1M | $75.0M | $124.5M | $118.3M |
| Shareholders' equity | $155.2M | $263.1M | $313.6M | $439.9M | $433.1M | $366.3M | $195.0M | $131.3M | -$29.1M | -$5.9M |
Growth · year-over-year · Revenue CAGR 31.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +7.9% | +25.7% | -6.7% | +14.0% | +40.9% | +37.7% | +97.0% | +70.9% | +27.7% | +15.6% |
| Net income growth | — | — | — | -707.7% | — | — | — | — | — | — |
| EPS growth | — | — | — | -712.5% | — | — | — | — | — | — |
| Free cash flow growth | -694.1% | — | -458.1% | -83.2% | — | -112.2% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.